Clinical Trial Update: Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis [Phase 2]

View source ↗

Summary

A Phase 2 trial of benralizumab (KHK4563) in patients with eosinophilic chronic rhinosinusitis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Chronic Rhinosinusitis

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Eosinophilic Chronic Rhinosinusitis | Phase 2 | Status: COMPLETED